Analysts have suggested that approval in CSU alone could make the drug a blockbuster, with sales of more than $1 billion a year, and Novartis is running phase 3 trials for chronic inducible urticaria (CINDU) and multiple sclerosis (MS), and phase 2 studies in hidradenitis suppurativa (HS) and food allergy indications
Malhotra adds that long-term cost-effectiveness should be evaluated, asking, Is it worth it to put people on these medications, or are there cheaper ways of achieving that same results, which, right now, I dont know what that would be
Bewaaradvies: Goed afgesloten, droog, koel en buiten het bereik van kinderen bewaren
All medications are sourced from licensed 503A compounding pharmacies and are HSA/FSA eligible, making precision weight loss therapy accessible to all 50 states without insurance